Pentavalent Market 2026–2035 supported by vaccination initiatives

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Pentavalent Market From 2026 To 2030?

The pentavalent market has experienced consistent expansion in its size over recent years. Projections indicate its expansion from $2.7 billion in 2025 to $2.83 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.6%. Historically, this growth is primarily due to factors such as increasing infant mortality rates, restricted vaccine access, the widespread occurrence of rotavirus infections, governmental vaccination programs, and worldwide public health efforts.

The pentavalent market size is projected to experience consistent expansion in the coming years. This market is anticipated to reach a valuation of $3.39 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.7%. This expansion during the projection period stems from factors such as advancements in vaccine formulation technology, a rise in healthcare spending, the broadening of immunization initiatives in emerging nations, collaborations among pharmaceutical firms, and the adoption of digital tracking systems for vaccine coverage. Key trends for the forecast period encompass an increase in infant immunization programs, governmental financial support for vaccine creation, an enhancement of public health infrastructure, greater public understanding of rotavirus prevention, and the development of cold chain logistics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9104&type=smp

What Drivers Are Influencing The Pentavalent Market?

The growing incidence of diphtheria is projected to fuel the expansion of the pentavalent market in the coming years. Diphtheria, a severe and highly contagious illness caused by the bacterium Corynebacterium diphtheriae, leads to significant challenges with ingestion and respiration, alongside potential skin lesions. The pentavalent vaccine offers protection against Diphtheria through a 3-dose immunization schedule for children, thereby the increasing occurrence of diphtheria has heightened the need for pentavalent vaccines. For example, data from July 2025 by the European Centre for Disease Prevention and Control, a Europe-based governmental body, revealed a total of 126 laboratory-confirmed cases of C. diphtheriae ST574 across Germany, comprising 55 cases in 2022, 49 in 2023, 18 in 2024, and at least 4 in 2025. Consequently, the increasing prevalence of diphtheria is a key factor propelling the expansion of the pentavalent market.

Pentavalent Market Driver: Increasing Healthcare Expenditure To Propel Pentavalent Market Growth

Increased healthcare spending is anticipated to stimulate the expansion of the pentavalent market in the future. This expenditure denotes the comprehensive financial and other resources utilized for delivering health services over a defined period. Specifically for pentavalent, it represents the funds dedicated to the research, manufacturing, dissemination, and delivery of vaccines that offer protection against five distinct diseases. As an illustration, the Centers for Medicare & Medicaid Services, a US-based agency overseeing Medicare and Medicaid, reported in December 2024 that U.S. health care expenditures in 2023 grew by 7.5%, reaching $4.9 trillion, equating to approximately $14,570 per person. Thus, the growing healthcare expenditure is acting as a catalyst for the pentavalent market’s growth.

Which Segments Are Included In The Analysis Of The Pentavalent Market?

The pentavalent market covered in this report is segmented –

1) By Type: Pentavalent Vaccines (DTP-HepB-Hib combination), Other Combination Vaccines

2) By Formulation Type: Lyophilized, Liquid

3) By Application: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Pentavalent Vaccines (DTP-HepB-Hib combination): DTP-HepB-Hib (Whole Cell), DTP-HepB-Hib (Acellular)

2) By Other Combination Vaccines: Hexavalent Vaccines

Which Trends Are Impacting The Growth Of The Pentavalent Market?

Leading firms within the pentavalent market prioritize the creation of advanced solutions, including pentavalent immunization vaccines. These pentavalent immunization vaccines represent a form of combination vaccine, engineered to offer defense against five distinct illnesses. As an illustration, during October 2023, Pfizer, a pharmaceutical firm based in the US, disclosed that its ‘Penbraya’ pentavalent vaccine received FDA approval. This stands as the first and only pentavalent vaccine offering defense against the five most common meningococcal serogroups, specifically A, B, C, W-135, and Y, for people from 10 to 25 years of age. The vaccine integrates components from the Trumenba meningococcal group B vaccine and the Nimenrix meningococcal groups A, C, W-135, and Y conjugate vaccine. Penbraya has demonstrated effectiveness in safeguarding against the five meningococcal serogroups that cause most instances of invasive meningococcal disease worldwide.

Which Key Industry Participants Are Active In The Pentavalent Market?

Major companies operating in the pentavalent market are Pfizer Inc., Merck & Co Inc., Sanofi SA, GlaxoSmithKline plc, Shandong Xinhua Pharmaceutical Company Limited, PT Bio Farma (Persero), Shantha Biotechnics Limited, Biological E. Limited, Serum Institute of India Private Limited, Indian Immunologicals Limited, Incepta Pharmaceuticals Limited, Shanghai Institute of Biological Products Co Ltd., Changchun Changsheng Biotechnology Co Ltd., Adimmune Corporation, AJ Vaccines, Albert David Limited, PanGen Biotech Inc., Bharat Biotech International Limited, Vacsera Ltd., Pasteur Institute of India, Zydus Cadila Healthcare Limited, EuBiologics Co Ltd.

Read the full pentavalent market report here:

https://www.thebusinessresearchcompany.com/report/pentavalent-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Pentavalent Market?

Asia-Pacific was the largest region in the pentavalent market in 2025. The regions covered in the pentavalent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Pentavalent Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9104&type=smp

Browse Through More Reports Similar to the Global Pentavalent Market 2026, By The Business Research Company

Pentavalent Market Report 2026

https://www.thebusinessresearchcompany.com/report/pentavalent-global-market-report

Pentavalent Market Report 2026

https://www.thebusinessresearchcompany.com/report/pentavalent-global-market-report

Quadrivalent Market Report 2026

https://www.thebusinessresearchcompany.com/report/quadrivalent-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795